R C Shelton

Summary

Affiliation: Vanderbilt University
Country: USA

Publications

  1. ncbi Treatment options for refractory depression
    R C Shelton
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tenn 37212, USA
    J Clin Psychiatry 60:57-61; discussion 62-3. 1999
  2. ncbi Can recovery from depression be achieved?
    R C Shelton
    Vanderbilt University Medical Center in Nashville, Tennesse, USA
    Psychiatr Serv 52:1469-78. 2001
  3. ncbi St John's wort for the treatment of depression
    Richard C Shelton
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN, USA
    Lancet Neurol 1:275. 2002
  4. ncbi Mechanisms of action in the treatment of anxiety
    R C Shelton
    Department of Psychiatry, Vanderbilt University Medical Center, Nashville, Tenn 37121 8646, USA
    J Clin Psychiatry 62:10-5. 2001
  5. ncbi Effectiveness of St John's wort in major depression: a randomized controlled trial
    R C Shelton
    Department of Psychiatry, Vanderbilt University, Nashville Tennessee, USA
    JAMA 285:1978-86. 2001
  6. ncbi Cellular mechanisms in the vulnerability to depression and response to antidepressants
    R C Shelton
    Departments of Psychiatry and Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Psychiatr Clin North Am 23:713-29. 2000
  7. ncbi A novel augmentation strategy for treating resistant major depression
    R C Shelton
    Department of Psychiatry, Vanderbilt University Medical Center, Nashville, TN 37212, USA
    Am J Psychiatry 158:131-4. 2001
  8. ncbi Mood-stabilizing drugs in depression
    R C Shelton
    Department of Psychiatry, Vanderbilt University, Nashville, Tenn, USA
    J Clin Psychiatry 60:37-40; discussion 41-2. 1999
  9. ncbi Cross-talk between PKA and PKC in human fibroblasts: what are the pharmacotherapeutic implications?
    D H Manier
    Department of Psychiatry, Vanderbilt University Medical Center, Nashville, TN 37232 2647, USA
    J Affect Disord 65:275-9. 2001
  10. ncbi Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression
    R C Shelton
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN, and McLean Hospital, Belmont, MA, USA
    Int J Clin Pract 61:1337-48. 2007

Collaborators

Detail Information

Publications61

  1. ncbi Treatment options for refractory depression
    R C Shelton
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tenn 37212, USA
    J Clin Psychiatry 60:57-61; discussion 62-3. 1999
    ..g., SSRI plus serotonin norepinephrine reuptake inhibitor [NSRI] or higher doses of venlafaxine or fluoxetine), steroid suppression therapy, augmentation with atypical antipsychotics, and psychotherapy...
  2. ncbi Can recovery from depression be achieved?
    R C Shelton
    Vanderbilt University Medical Center in Nashville, Tennesse, USA
    Psychiatr Serv 52:1469-78. 2001
    ..Serotonergic agents would be chosen for monotherapy or augmentation for symptoms of distress. Alternatively, catecholaminergic drugs would be the first choice for anhedonia and decreased motivation...
  3. ncbi St John's wort for the treatment of depression
    Richard C Shelton
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN, USA
    Lancet Neurol 1:275. 2002
  4. ncbi Mechanisms of action in the treatment of anxiety
    R C Shelton
    Department of Psychiatry, Vanderbilt University Medical Center, Nashville, Tenn 37121 8646, USA
    J Clin Psychiatry 62:10-5. 2001
    ..Basic research and clinical research suggest that serotonergic agents may be preferentially effective for symptoms of general distress, whereas catecholaminergic agents may target anhedonic depression symptoms...
  5. ncbi Effectiveness of St John's wort in major depression: a randomized controlled trial
    R C Shelton
    Department of Psychiatry, Vanderbilt University, Nashville Tennessee, USA
    JAMA 285:1978-86. 2001
    ..Extracts of St John's wort are widely used to treat depression. Although more than 2 dozen clinical trials have been conducted with St John's wort, most have significant flaws in design and do not enable meaningful interpretation...
  6. ncbi Cellular mechanisms in the vulnerability to depression and response to antidepressants
    R C Shelton
    Departments of Psychiatry and Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Psychiatr Clin North Am 23:713-29. 2000
    ..As the complex interactions of these systems gradually yield to investigation, not only will new treatments be developed, but better matching of treatment to patient may become an achievable goal...
  7. ncbi A novel augmentation strategy for treating resistant major depression
    R C Shelton
    Department of Psychiatry, Vanderbilt University Medical Center, Nashville, TN 37212, USA
    Am J Psychiatry 158:131-4. 2001
    ..The authors hypothesized that fluoxetine could be augmented with olanzapine to successfully treat resistant depression...
  8. ncbi Mood-stabilizing drugs in depression
    R C Shelton
    Department of Psychiatry, Vanderbilt University, Nashville, Tenn, USA
    J Clin Psychiatry 60:37-40; discussion 41-2. 1999
    ..The effects of antipsychotics (especially atypicals) and new research directions also will be reviewed...
  9. ncbi Cross-talk between PKA and PKC in human fibroblasts: what are the pharmacotherapeutic implications?
    D H Manier
    Department of Psychiatry, Vanderbilt University Medical Center, Nashville, TN 37232 2647, USA
    J Affect Disord 65:275-9. 2001
    ....
  10. ncbi Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression
    R C Shelton
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN, and McLean Hospital, Belmont, MA, USA
    Int J Clin Pract 61:1337-48. 2007
    ....
  11. ncbi Psychiatric profile and attention deficits in postural tachycardia syndrome
    V Raj
    Department of Psychiatry, Vanderbilt University School of Medicine, 1500 21st Ave, South, Nashville, TN 37212, USA
    J Neurol Neurosurg Psychiatry 80:339-44. 2009
    ..Patients with POTS were formally assessed for psychiatric disorders and inattention and compared with patients with attention deficit hyperactivity disorder (ADHD) and control subjects...
  12. ncbi Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A
    R C Shelton
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN 37212, USA
    Neuroscience 158:1406-15. 2009
    ..The correlation of 5-HT(2A) receptor levels with PKA activity in the depressed group suggests that abnormalities of 5-HT(2A) receptor abundance may depend on receptor uncoupling and heterologous regulation by PKA...
  13. ncbi Detection of an mRNA polymorphism by differential display
    S Liang
    Department of Psychiatry, Vanderbilt University Medical Center, Nashville, TN, USA
    Mol Biotechnol 19:121-4. 2001
    ..Polymorphic transcripts of a single gene differing by one tandem repeat sequence of four nucleotides (TGAT) in the 3' noncoding region were detected...
  14. ncbi Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression
    R C Shelton
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN 37212, USA
    Mol Psychiatry 16:751-62. 2011
    ..The results of this study indicate that post-mortem brain tissue samples from BA10, a region that is involved in reward-related behavior, show evidence of local inflammatory, apoptotic, and oxidative stress in MDD...
  15. ncbi Serum thyrotropin concentrations and bioactivity during sleep deprivation in depression
    D N Orth
    Psychiatry Service (116A, Department of Veterans Affairs Medical Center, 1310 24th Ave S, Nashville, TN 37212-2637, USA
    Arch Gen Psychiatry 58:77-83. 2001
    ..Sleep deprivation responders compensate by secreting more thyrotropin with normal bioactivity; nonresponders compensate by secreting thyrotropin with increased bioactivity...
  16. ncbi Noradrenergic antidepressants: does chronic treatment increase or decrease nuclear CREB-P?
    D H Manier
    Department of Psychiatry and Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232 2647, USA
    J Neural Transm 109:91-9. 2002
    ....
  17. ncbi A randomized, double-blind, crossover trial of modafinil on mood
    Indu Taneja
    Department of Pharmacology, Dysfunction Center, Division of Clinical Pharmacology, Vanderbilt University, Nashville, TN 37232 2195, USA
    J Clin Psychopharmacol 27:76-9. 2007
    ..The findings may have implications for clinical practice, in particular for the adjunctive use of modafinil in treatment-resistant depression...
  18. ncbi Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer
    Janet S Carpenter
    Indiana University, 1111 Middle Drive NU340D, Indianapolis, Indiana 46202, USA
    Oncologist 12:124-35. 2007
    ....
  19. ncbi A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder
    Richard C Shelton
    Department of Psychiatry, Vanderbilt University Medical Center, Nashville, Tenn, USA
    J Clin Psychiatry 67:1674-81. 2006
    ..The objective of the current multisite study was to compare relatively higher doses of sertraline (i.e., 150 mg/day) and venlafaxine extended release (XR) (225 mg/day) in outpatients with major depressive disorder...
  20. ncbi Progressive resistance to a selective serotonin reuptake inhibitor but not to cognitive therapy in the treatment of major depression
    Yan Leykin
    Department of Psychology, University of Pennsylvania, Philadelphia, PA 19104 6196, USA
    J Consult Clin Psychol 75:267-76. 2007
    ..If these findings are replicated in methodologically rigorous studies of paroxetine and other antidepressants, CT should be recommended, in preference to AD, for patients with multiple prior AD exposures...
  21. ncbi Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents
    George I Papakostas
    Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, Boston, MA 02114, USA
    Biol Psychiatry 62:1217-27. 2007
    ..The goal of our work was to compare response rates among patients with MDD treated with either of these two broad categories of antidepressant drugs...
  22. ncbi Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 68:826-31. 2007
    ..To examine the efficacy and overall tolerability of augmentation of standard antidepressants with atypical antipsychotic agents for treatment-resistant major depressive disorder...
  23. ncbi Use of treatment algorithms for depression
    Madhukar H Trivedi
    Mood Disorders Program and Clinic, Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA
    J Clin Psychiatry 67:1458-65. 2006
  24. ncbi The molecular neurobiology of depression
    Richard C Shelton
    Department of Psychiatry, Vanderbilt University Medical Center, 1500 21st Avenue, South, Suite 2200, Nashville, TN 37212, USA
    Psychiatr Clin North Am 30:1-11. 2007
    ..Doing so could lead to the development of novel interventions that could target specific points of vulnerability, allowing an improved matching of patient to treatment based on differential abnormalities at the cellular level...
  25. ncbi Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study
    David L Dunner
    Center for Anxiety and Depression and the Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, USA
    J Clin Psychiatry 68:1071-7. 2007
    ..To evaluate the efficacy and tolerability of adjunctive ziprasidone in subjects with treatment-resistant major depressive disorder (DSM-IV criteria) without psychotic features...
  26. ncbi Sequence of improvement in depressive symptoms across cognitive therapy and pharmacotherapy
    Sunil S Bhar
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Affect Disord 110:161-6. 2008
    ..The authors examined the patterns of improvement in cognitive and vegetative symptoms of major depression in individuals treated with cognitive therapy (CT) or pharmacotherapy (PT)...
  27. ncbi Antidepressant medications v. cognitive therapy in people with depression with or without personality disorder
    Jay C Fournier
    Department of Psychology, University of Pennsylvania, Philadelphia, PA 19104 6196, USA
    Br J Psychiatry 192:124-9. 2008
    ..There is conflicting evidence about comorbid personality pathology in depression treatments...
  28. ncbi Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder
    Richard C Shelton
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN, USA
    Acta Psychiatr Scand 117:253-9. 2008
    ..Atypical antipsychotics (AAPs) have been hypothesized to be beneficial in treatment-resistant depression (TRD). This paper will review a biochemical rationale and will summarize the data regarding the effectiveness of AAPs in TRD...
  29. ncbi Bipolar depression: best practices for the outpatient
    Paul E Keck
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH, USA
    CNS Spectr 12:1-14. 2007
    ..Two case studies are presented to elucidate the best practices for the varying clinical states of bipolar disorder...
  30. ncbi Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study
    James H Kocsis
    Department of Psychiatry, Weill Cornell Medical College, New York, NY 10012, USA
    J Clin Psychiatry 68:1014-23. 2007
    ..To test the long-term efficacy and safety of venlafaxine extended-release (ER) in preventing recurrence in patients with major depression...
  31. ncbi Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression
    Richard C Shelton
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Int Clin Psychopharmacol 22:348-55. 2007
    ....
  32. ncbi Augmentation strategies to increase antidepressant efficacy
    Richard C Shelton
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN, USA
    J Clin Psychiatry 68:18-22. 2007
    ..Beyond antidepressants and antipsychotics, alternative augmentation strategies include emerging pharmacologic treatments and nonpharmacologic strategies...
  33. ncbi The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases
    Martin B Keller
    Department of Psychiatry and Human Behavior, Brown University, Providence, RI 02906, USA
    J Clin Psychiatry 68:1246-56. 2007
    ..To report second-year results from the 2-year maintenance phase of a long-term study to evaluate the efficacy and safety of venlafaxine extended release (ER) in preventing recurrence of depression...
  34. ncbi The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases
    Martin B Keller
    Brown University, Providence, Rhode Island 02906, USA
    Biol Psychiatry 62:1371-9. 2007
    ..We evaluated the comparative efficacy and safety of venlafaxine extended release (ER) and fluoxetine in the acute and continuation phases of treatment...
  35. ncbi Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies
    Michael E Thase
    University of Pittsburgh Medical Center, Department of Psychiatry, Pittsburgh, PA 15213 2593, USA
    J Clin Psychopharmacol 26:250-8. 2006
    ....
  36. ncbi Differential expression of pentraxin 3 in fibroblasts from patients with major depression
    Richard C Shelton
    Department of Psychiatry, Vanderbilt University Medical Center, Nashville, TN 37211, USA
    Neuropsychopharmacology 29:126-32. 2004
    ..The results are of potential importance because PTX3 is a member of the long pentraxin subfamily of acute-phase proteins, which is inducible by IL-1beta, and may play roles in neuroimmunity and neuroprotection...
  37. ncbi Do venlafaxine XR and paroxetine equally influence negative and positive affect?
    Gabriel S Dichter
    Department of Psychology, College of Arts and Sciences, Wilson Hall, Vanderbilt University, Nashville TN 37203, USA
    J Affect Disord 85:333-9. 2005
    ....
  38. ncbi The combination of olanzapine and fluoxetine in mood disorders
    Richard C Shelton
    1500 21 Avenue, South, Suite 2200, Nashville, TN 37212, USA
    Expert Opin Pharmacother 4:1175-83. 2003
    ..These problems will have to be vigorously addressed in order to achieve a substantial market penetration for these conditions...
  39. ncbi Risperidone and paroxetine given singly and in combination for bipolar depression
    Richard C Shelton
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN 37212, USA
    J Clin Psychiatry 65:1715-9. 2004
    ..The current study was intended to evaluate the effects of the novel antipsychotic risperidone, the selective serotonin reup-take inhibitor (SSRI) paroxetine, and the combination in patients with bipolar disorder...
  40. ncbi The dual-action hypothesis: does pharmacology matter?
    Richard C Shelton
    Department of Psychiatry, Vanderbilt University School of Medicine, 1500 21st Ave, South, Suite 2200, Nashville, TN 37212, USA
    J Clin Psychiatry 65:5-10. 2004
    ..This review compares the neurobiology of single- and dual-action mechanisms...
  41. ncbi Signal transduction abnormalities in melancholic depression
    Demet Akin
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN 37212, USA
    Int J Neuropsychopharmacol 8:5-16. 2005
    ..These data further implicate signal transduction abnormalities in melancholic major depression, particularly PKA and PKC. This suggests an abnormality of factors controlling the expression or degradation of these enzymes...
  42. ncbi The effectiveness of St. John's Wort in major depressive disorder: a naturalistic phase 2 follow-up in which nonresponders were provided alternate medication
    Alan J Gelenberg
    University of Arizona Health Sciences Center, Tucson, AZ 85724, USA
    J Clin Psychiatry 65:1114-9. 2004
    ..A continuation study of an extract of St. John's wort (Hypericum perforatum) for depression was performed in follow-up to an acute study that found no significant difference between St. John's wort extract and placebo...
  43. ncbi Decreased serotonin 5-HT2A receptor-stimulated phosphoinositide signaling in fibroblasts from melancholic depressed patients
    Demet Akin
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN, USA
    Neuropsychopharmacology 29:2081-7. 2004
    ..The data raise the possibility that the reduced 5-HT(2A) receptor-induced PI hydrolysis is intrinsic to the receptor itself or its coupling to Gq protein, and is not related to altered availability of the 5-HT(2A) receptor, Gq or PLC...
  44. ncbi Early- and late-onset startle modulation in unipolar depression
    Gabriel S Dichter
    Department of Psychology, College of Arts and Science, Vanderbilt University, Nashville, Tennessee 37203, USA
    Psychophysiology 41:433-40. 2004
    ....
  45. ncbi Assessing the effects of bupropion SR on mood dimensions of depression
    Andrew J Tomarken
    Department of Psychology, College of Arts and Sciences, Vanderbilt University, Nashville, TN 37203, USA
    J Affect Disord 78:235-41. 2004
    ....
  46. ncbi Cognitive therapy vs medications in the treatment of moderate to severe depression
    Robert J Derubeis
    Department of Psychology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Arch Gen Psychiatry 62:409-16. 2005
    ..There is substantial evidence that antidepressant medications treat moderate to severe depression effectively, but there is less data on cognitive therapy's effects in this population...
  47. ncbi Prevention of relapse following cognitive therapy vs medications in moderate to severe depression
    Steven D Hollon
    Department of Psychology, Vanderbilt University, 306 Wilson Hall Nashville, TN 37203, USA
    Arch Gen Psychiatry 62:417-22. 2005
    ..Antidepressant medication prevents the return of depressive symptoms, but only as long as treatment is continued...
  48. ncbi Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research
    Alan F Schatzberg
    Stanford University School of Medicine, Stanford, Calif 94305 5717, USA
    J Clin Psychiatry 67:27-30. 2006
    ..This article summarizes recommendations with respect to future research as well as clinical management recommendations for SRI discontinuation syndrome...
  49. ncbi The nature of the discontinuation syndrome associated with antidepressant drugs
    Richard C Shelton
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tenn 37212, USA
    J Clin Psychiatry 67:3-7. 2006
    ..As a result, it is vital that both patients and their relatives, especially caregivers, be provided with adequate education and a realistic and objective appraisal of expected outcomes upon initiation of antidepressant treatment...
  50. ncbi Olanzapine/fluoxetine combination for bipolar depression
    Richard C Shelton
    Department of Psychiatry, Vanderbilt University Medical Center, Nashville, TN 37212, USA
    Expert Rev Neurother 6:33-9. 2006
    ..However, many clinicians find management of weight gain in olanzapine treated patients a challenge. In addition, weight, waist circumference, lipids and glucose should be monitored...
  51. ncbi Detection of an mRNA polymorphism by differential display
    Shan Liang
    Department of Psychiatry, Vanderbilt University Medical Center, Nashville, TN, USA
    Methods Mol Biol 317:279-85. 2006
    ..Polymorphic transcripts of a single gene differing by one tandem repeat sequence of four nucleotides (TGAT) in the 3' noncoding region were detected...
  52. ncbi Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance
    Richard C Shelton
    Department of Psychiatry, Vanderbilt University, Nashville, TN 37212, USA
    J Clin Psychiatry 66:1289-97. 2005
    ....
  53. ncbi Presenting characteristics of depressed outpatients as a function of recurrence: preliminary findings from the STAR*D clinical trial
    Steven D Hollon
    Department of Psychology, Vanderbilt University, 306 Wilson Hall, Nashville, TN 37203, United States
    J Psychiatr Res 40:59-69. 2006
    ..Recurrent depression predicts risk for subsequent episodes, but it is unclear how it relates to demographic features, course of illness, and clinical presentation...
  54. ncbi The use of antidepressants in novel combination therapies
    Richard C Shelton
    Adult Psychiatry Division, Department of Psychiatry, Vanderbilt University Medical Center, Nashville, TN 37212 8646, USA
    J Clin Psychiatry 64:14-8. 2003
    ..However, more research is needed to corroborate these early results...
  55. ncbi Treating bipolar depression
    Richard C Shelton
    Vanderbilt University School of Medicine, Nashville, TN, USA
    J Fam Pract . 2003
  56. ncbi Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features
    A John Rush
    Department of Psychiatry, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 9086, USA
    J Affect Disord 87:43-55. 2005
    ..This study evaluated the clinical and sociodemographic features associated with various degrees of concurrent comorbidity in adult outpatients with nonpsychotic major depressive disorder (MDD)...
  57. ncbi Polymorphisms in the regulatory region of the human serotonin 5-HT2A receptor gene (HTR2A) influence gene expression
    Regina L Myers
    Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232 8548, USA
    Biol Psychiatry 61:167-73. 2007
    ..Genomic variation in the regulatory region of the serotonin (5-HT) 2A receptor gene (HTR2A) may contribute to altered levels of 5-HT2A receptor and to psychiatric disease...
  58. ncbi The relation of patients' treatment preferences to outcome in a randomized clinical trial
    Yan Leykin
    Department of Psychology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Behav Ther 38:209-17. 2007
    ..These results do not provide support for the claim that the external validity of randomized controlled trials suffers from this aspect of the randomization procedure...
  59. ncbi Human serotonin transporter variants display altered sensitivity to protein kinase G and p38 mitogen-activated protein kinase
    Harish C Prasad
    Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232 8548, USA
    Proc Natl Acad Sci U S A 102:11545-50. 2005
    ....
  60. ncbi Sequence variation in the human dopamine transporter gene in children with attention deficit hyperactivity disorder
    Michelle S Mazei-Robison
    Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232 8548, USA
    Neuropharmacology 49:724-36. 2005
    ..Interestingly, the A559V variant was previously identified in a subject with bipolar disorder [. Molecular Psychiatry 5, 275], a psychiatric disorder that has a significant number of overlapping symptoms with ADHD...
  61. ncbi Are depressed outpatients with and without a family history of substance use disorder different? A baseline analysis of the STAR*D cohort
    Lori L Davis
    Department of Veterans Affairs VA Medical Center, Tuscaloosa, Ala 35404, USA
    J Clin Psychiatry 68:1931-8. 2007
    ....